Prediction of metabolic and transporter-mediated DDI upon concomitant administration of rivaroxaban with amiodarone, dronedarone, and their metabolites using mechanistic static modeling
| Precipitant | Predicted AUC Fold Change | ||
|---|---|---|---|
| Inhibition of Hepatic Metabolism | Inhibition of Hepatic and Gut Metabolism | Inhibition of P-gp–Mediated Efflux | |
| Amiodarone | 1.22 | 1.37 | 1.09 |
| NDEA | 1.22 | NA | 1.13 |
| Dronedarone | 1.17 | 1.31 | 1.09 |
| NDBD | 1.26 | NA | ND |
NA, not applicable; ND, not determined.